We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 103.22 | 0 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Novartis AG on Monday said the U.S. Food and Drug Administration granted a pair of breakthrough-therapy designations to asciminib, its investigational treatment specifically targeting the ABL myristoyl pocket in chronic myeloid leukemia.
The Swiss drug maker said the designations cover asciminib for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with two or more tyrosine kinase inhibitors, and those who harbor the T315I mutation.
The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.
Novartis, which is developing asciminib across multiple treatment lines of chronic myeloid leukemia, said it plans to file for U.S. Food and Drug Administration approval in pre-treated patients in the first half of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 08, 2021 08:17 ET (13:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
